[go: up one dir, main page]

AR011077A1 - A CRYSTALLINE ANTIBIOTIC DESIGNATED 6-O-METHYLERYTHROMYCIN A FORM 0, A COMPOSITION UNDERSTANDING IT, A METHOD FOR TREATING BACTERIAL INFECTIONS IN A MAMMAL, A PROCEDURE FOR PREPARING SUCH SOLVATE; A COMPLEX THAT INCLUDES SAID SOLVATO, A SUSPENSION FOR ADMINISTRATION - Google Patents

A CRYSTALLINE ANTIBIOTIC DESIGNATED 6-O-METHYLERYTHROMYCIN A FORM 0, A COMPOSITION UNDERSTANDING IT, A METHOD FOR TREATING BACTERIAL INFECTIONS IN A MAMMAL, A PROCEDURE FOR PREPARING SUCH SOLVATE; A COMPLEX THAT INCLUDES SAID SOLVATO, A SUSPENSION FOR ADMINISTRATION

Info

Publication number
AR011077A1
AR011077A1 ARP980100207A ARP980100207A AR011077A1 AR 011077 A1 AR011077 A1 AR 011077A1 AR P980100207 A ARP980100207 A AR P980100207A AR P980100207 A ARP980100207 A AR P980100207A AR 011077 A1 AR011077 A1 AR 011077A1
Authority
AR
Argentina
Prior art keywords
methylerythromycin
solvate
mammal
suspension
bacterial infections
Prior art date
Application number
ARP980100207A
Other languages
Spanish (es)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR011077A1 publication Critical patent/AR011077A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un antibiotico cristalino designado forma 0 de solvato de 6-O- metileritromicina A, que tiene la estructura (S), donde S es una moléculasolvatante seleccionada del grupo que consiste en etanol, acetato de ispropilo, isopropanol y tetrahidrofurano; una composicion que lo comprende, unmétodo para tratar infecciones bacterianas en un mamífero, un procedimiento para su preparacion y una suspension para administracion oral.A designated crystalline antibiotic forms 0-6-O-methylerythromycin A solvate, having structure (S), where S is a solvent molecule selected from the group consisting of ethanol, ispropyl acetate, isopropanol, and tetrahydrofuran; a composition comprising it, a method for treating bacterial infections in a mammal, a method for its preparation and a suspension for oral administration.

ARP980100207A 1997-01-17 1998-01-16 A CRYSTALLINE ANTIBIOTIC DESIGNATED 6-O-METHYLERYTHROMYCIN A FORM 0, A COMPOSITION UNDERSTANDING IT, A METHOD FOR TREATING BACTERIAL INFECTIONS IN A MAMMAL, A PROCEDURE FOR PREPARING SUCH SOLVATE; A COMPLEX THAT INCLUDES SAID SOLVATO, A SUSPENSION FOR ADMINISTRATION AR011077A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Publications (1)

Publication Number Publication Date
AR011077A1 true AR011077A1 (en) 2000-08-02

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980100207A AR011077A1 (en) 1997-01-17 1998-01-16 A CRYSTALLINE ANTIBIOTIC DESIGNATED 6-O-METHYLERYTHROMYCIN A FORM 0, A COMPOSITION UNDERSTANDING IT, A METHOD FOR TREATING BACTERIAL INFECTIONS IN A MAMMAL, A PROCEDURE FOR PREPARING SUCH SOLVATE; A COMPLEX THAT INCLUDES SAID SOLVATO, A SUSPENSION FOR ADMINISTRATION
ARP030101427A AR039666A2 (en) 1997-01-17 2003-04-24 PROCEDURE FOR THE PREPARATION OF THE VACUUM FORM OF 6-O-METHYLERYCHROMYCIN, SUCH CRYSTAL COMPOUND ISOLATED AS WELL AS ITS DERIVATIVES, THE USE OF THE SAME FOR THE PREPARATION OF AN ANTIBIOTIC, THE USE OF THE FORM 0 TO PREPARE IT FORM I 6-O-METHYLERTHROMYCIN AND OTHER DERIVATIVES
ARP030101428A AR039667A2 (en) 1997-01-17 2003-04-24 PROCEDURE FOR THE PREPARATION OF THE FORM II OF 6-O-METHYLEROMROMYCIN IN VACUUM, SUCH CRYSTAL COMPOUND ISOLATED AS WELL AS ITS DERIVATIVES, THE USE OF THE SAME FOR THE PREPARATION OF AN ANTIBIOTIC, THE USE OF THE FORM 0 TO PREPARE THE FORM II OF 6-O-METHYLERTHROMYCIN AND OTHER DERIVATIVES

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP030101427A AR039666A2 (en) 1997-01-17 2003-04-24 PROCEDURE FOR THE PREPARATION OF THE VACUUM FORM OF 6-O-METHYLERYCHROMYCIN, SUCH CRYSTAL COMPOUND ISOLATED AS WELL AS ITS DERIVATIVES, THE USE OF THE SAME FOR THE PREPARATION OF AN ANTIBIOTIC, THE USE OF THE FORM 0 TO PREPARE IT FORM I 6-O-METHYLERTHROMYCIN AND OTHER DERIVATIVES
ARP030101428A AR039667A2 (en) 1997-01-17 2003-04-24 PROCEDURE FOR THE PREPARATION OF THE FORM II OF 6-O-METHYLEROMROMYCIN IN VACUUM, SUCH CRYSTAL COMPOUND ISOLATED AS WELL AS ITS DERIVATIVES, THE USE OF THE SAME FOR THE PREPARATION OF AN ANTIBIOTIC, THE USE OF THE FORM 0 TO PREPARE THE FORM II OF 6-O-METHYLERTHROMYCIN AND OTHER DERIVATIVES

Country Status (18)

Country Link
US (1) US5945405A (en)
EP (1) EP1077988A1 (en)
JP (3) JP4058114B2 (en)
KR (1) KR100567149B1 (en)
CN (1) CN1174991C (en)
AR (3) AR011077A1 (en)
AU (1) AU735598B2 (en)
BR (1) BR9714287A (en)
CA (4) CA2387356C (en)
CZ (1) CZ297433B6 (en)
DE (1) DE97951771T1 (en)
ES (1) ES2173058T1 (en)
IL (1) IL130255A0 (en)
NZ (1) NZ336073A (en)
TR (1) TR199901578T2 (en)
TW (1) TW574224B (en)
WO (1) WO1998031699A1 (en)
ZA (1) ZA98116B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (en) * 1998-09-09 2003-08-19 한미약품공업 주식회사 Method for preparing Form 2 of clarithromycin without residual solvent
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (en) * 1999-10-21 2002-02-06 민경윤 Method of preparing form ii crystals of clarithromycin and clarithromycin formate used therein
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
YU45602A (en) * 1999-12-16 2005-06-10 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
FR2802534B1 (en) * 1999-12-20 2002-02-01 Merial Sas PROCESS FOR PREPARING AND ISOLATING 9-DEOXO-9 (Z) - HYDROXYIMINOERYTHROMYCIN A
DE60018119T2 (en) * 2000-01-11 2006-05-04 Teva Pharmaceutical Industries Ltd. PROCESS FOR PREPARING POLYMORPHES OF CLARITHROMYCIN
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2401571A1 (en) * 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
ES2242668T3 (en) * 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. METHOD FOR OBTAINING CLARITROMYCIN IN CRYSTALS OF FORM II.
KR100367981B1 (en) * 2000-11-23 2003-01-14 한미약품공업 주식회사 Process for preparing form ii crystals of clarithromycin and crystalline clarithromycin mesilate trihydrate used therein
MXPA02009587A (en) * 2000-03-28 2003-05-14 Biochemie Gmbh Granulated particles with masked taste.
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
DE60143360D1 (en) * 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Composition for the transdermal and / or transmucosal administration of active ingredients which guarantees adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
KR100408848B1 (en) * 2001-03-12 2003-12-06 주식회사 씨트리 Purification process of Clarithromycin
RU2217160C2 (en) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Method for topical treatment of urogenital chlamydiosis in women
PT1411899E (en) * 2001-08-01 2009-04-24 Novartis Ag Taste masking composition
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (en) * 2003-03-02 2008-10-22 王凌峰 A-type crystal of Clarithromycin
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
JP2006528185A (en) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (en) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
MXPA06003316A (en) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
JP2008505124A (en) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション Pulse delivery tablets
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (en) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph of Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (en) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 A kind of Clarithromycin crystal form transformation method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS60214796A (en) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd Production method of 6-0-methylerythromycins
JPS61103890A (en) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6-0-methylerythromycin A derivative
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (en) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd ERYTHROMYCIN-A DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
JPH0755958B2 (en) * 1986-10-03 1995-06-14 大正製薬株式会社 Method for producing erythromycin A derivative
KR960000434B1 (en) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 Erythromycin A derivatives and preparation method thereof
JP2526951B2 (en) * 1986-12-17 1996-08-21 大正製薬株式会社 Erythromycin A derivative and method for producing the same
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (en) * 1988-05-19 1998-05-18 大正製薬株式会社 Process for producing erythromycin A oxime and its salt
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
DK0915899T3 (en) * 1996-07-29 2004-11-29 Abbott Lab Preparation of crystalline form II of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
CA2387356C (en) 2003-05-27
CN1244869A (en) 2000-02-16
CA2387361C (en) 2003-05-27
JP2004075689A (en) 2004-03-11
KR20000070220A (en) 2000-11-25
CA2419499A1 (en) 1998-07-23
KR100567149B1 (en) 2006-04-04
CA2387356A1 (en) 1998-07-23
BR9714287A (en) 2000-04-18
JP2009137975A (en) 2009-06-25
CZ297433B6 (en) 2006-12-13
CA2277274C (en) 2003-05-27
TR199901578T2 (en) 1999-09-21
AU735598B2 (en) 2001-07-12
JP5190350B2 (en) 2013-04-24
DE97951771T1 (en) 2004-07-08
IL130255A0 (en) 2000-06-01
TW574224B (en) 2004-02-01
WO1998031699A1 (en) 1998-07-23
AR039666A2 (en) 2005-03-02
CA2277274A1 (en) 1998-07-23
ZA98116B (en) 1998-07-08
EP1077988A1 (en) 2001-02-28
AR039667A2 (en) 2005-03-02
NZ336073A (en) 2001-01-26
US5945405A (en) 1999-08-31
CA2387361A1 (en) 1998-07-23
CZ242699A3 (en) 1999-11-17
ES2173058T1 (en) 2002-10-16
CN1174991C (en) 2004-11-10
JP2000509725A (en) 2000-08-02
AU5532698A (en) 1998-08-07
JP4058114B2 (en) 2008-03-05

Similar Documents

Publication Publication Date Title
AR011077A1 (en) A CRYSTALLINE ANTIBIOTIC DESIGNATED 6-O-METHYLERYTHROMYCIN A FORM 0, A COMPOSITION UNDERSTANDING IT, A METHOD FOR TREATING BACTERIAL INFECTIONS IN A MAMMAL, A PROCEDURE FOR PREPARING SUCH SOLVATE; A COMPLEX THAT INCLUDES SAID SOLVATO, A SUSPENSION FOR ADMINISTRATION
RU95106362A (en) Lipopeptide derivatives, process for preparation thereof, pharmaceutical composition containing said derivatives, and process for preparation of said composition
NO2005020I2 (en) Caspofungin, optionally in the form of a pharmaceutically acceptable salt, especially caspofungi acetate
DE69104991D1 (en) MOMETASON FUROATE MONOHYDRATE, METHOD FOR THE PRODUCTION THEREOF AND THE CONTAINING PHARMACEUTICAL COMPOSITIONS.
RU94042922A (en) Novel compounds, method for their production, pharmaceutical composition
ES2196331T3 (en) MACROCICLICAL CHAIN DERIVATIVES OF 13 ELEMENTS OF ERYTHROMYCINS A AND B.
SE7613959L (en) ANTIBIOTIC COMPOSITION AND PROCEDURE FOR PREPARING IT
MA26458A1 (en) NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE69728420D1 (en) METHODS FOR TREATING CHLAMYDIA PNEUMONIAE HEART DISEASES
PT1042340E (en) OXYME OF 6-O-ALKYL-ERITROMYCIN B
DE3863366D1 (en) ANTIBIOTIC VERMISPORIN, METHOD FOR THE PRODUCTION THEREOF AND THE SAME PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN ACTIVE ANTIBACTERIAL ACTIVE SUBSTANCE.
DE58908740D1 (en) Tolypocladium varium fungus and process for the preparation of the antibiotic complex cyclosporin and / or its components.
EP0992509A3 (en) Novel macrolide derivatives
EP0137440A3 (en) Cephalasporin derivatives and process for their preparation
DE2967701D1 (en) A-21978 ANTIBIOTIC MIXTURE, METHOD FOR THE PRODUCTION THEREOF, THEIR PHARMACEUTICAL COMPOSITIONS AND PRODUCING MICROORGANISM.
MD1788F2 (en) Erythromycin A 9-O-oximes derivatives, pharmaceutical composition on base thereof and method of treatment of infectious diseases
DE69012650D1 (en) Piperidine derivative, process for its preparation and pharmaceutical composition containing the same.
ES2157899T3 (en) SAMPANGINA DERIVATIVES USEFUL AS ANTIFUNGIC AND ANTIMICOBACTERIAL AGENTS.
DK1007530T3 (en) 6-O-substituted erythromycin compounds and their method of preparation
ATE66610T1 (en) COLLOIDAL BASE GEL CONTAINING PRIMYCIN, PROCESS FOR PRODUCTION THEREOF, PHARMACEUTICAL AND PHARMACO-COSMETIC COMPOSITIONS CONTAINING THIS BASE GEL.
RU95107655A (en) Glucopyranoside benzothiophenes, method of synthesis, pharmaceutical composition
RU94007342A (en) NEW ERYTHROMYCIN DERIVATIVES, THEIR PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS
HUT57774A (en) Process for producing triacetate derivative of antibiotic bu-3420t, as well as pharmaceutical compositions comprising bu-3420t triacetate
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
DK1181300T3 (en) 6-O-carbamate ketolide derivatives

Legal Events

Date Code Title Description
FC Refusal